Journal of Controlled Release

2018

DOI: 10.1016/j.jconrel.2018.08.029

|View full text |Cite

|

Sign up to set email alerts

|

E-selectin-targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction

¹

,

²

,

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction3

Discussion1

Polymer–peptide and Polymer–nucleotide Conjugates1

Citation Types

Supporting

0

Mentioning

14

Contrasting

1

Year Published

2019

2019

2024

2024

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 35 publications

(16 citation statements)

References 47 publications

Supporting

0

Mentioning

14

Contrasting

1

Order By: Relevance

“…It controls inflammation in many diseases including atherosclerosis and HF. 27 , 28 , 29 Increased circulating levels of SELE are associated with an increased risk of developing essential hypertension and metabolic syndrome in women, which is an important risk factor for the development of HFpEF, a HF phenotype that is predominantly present in women. 30 , 31 , 32 IL1RA is a member of the interleukin‐1 family and is also involved in immunological and inflammatory processes.…”

Section: Discussionmentioning

confidence: 99%

Identification of sex‐specific biomarkers predicting new‐onset heart failure

¹

,

²

,

³

et al. 2021

ESC Heart Failure

View full text Add to dashboard Cite

Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF. Methods and results A matched case-control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER), follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P < 0.013). E-selectin and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for incident HF. Conclusions The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.

“…It controls inflammation in many diseases including atherosclerosis and HF. 27 , 28 , 29 Increased circulating levels of SELE are associated with an increased risk of developing essential hypertension and metabolic syndrome in women, which is an important risk factor for the development of HFpEF, a HF phenotype that is predominantly present in women. 30 , 31 , 32 IL1RA is a member of the interleukin‐1 family and is also involved in immunological and inflammatory processes.…”

Section: Discussionmentioning

confidence: 99%

Identification of sex‐specific biomarkers predicting new‐onset heart failure

¹

,

²

,

³

et al. 2021

ESC Heart Failure

View full text Add to dashboard Cite

Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF. Methods and results A matched case-control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER), follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P < 0.013). E-selectin and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for incident HF. Conclusions The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.

“…Moreover, the E‐selectin binding peptide containing polymers were shown to be effective in the case of the atherosclerotic plaque treatment and overall within the therapy of vascular inflammation. [ 47 ]…”

Section: Polymer–peptide and Polymer–nucleotide Conjugatesmentioning

confidence: 99%

Polymer‐Based Drug‐Free Therapeutics for Anticancer, Anti‐Inflammatory, and Antibacterial Treatment

¹

,

²

,

³

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

This paper summarizes the area of biomedicinal polymers, which serve as nanomedicines even though they do not contain any anticancer or antiinflammatory drugs. These polymer nanomedicines with unique design are in the literature highlighted as a novel class of therapeutics called “drug‐free macromolecular therapeutics.” Their therapeutic efficacy is based on the tailored multiple presentations of biologically active vectors, i.e., peptides, oligopeptides, or oligosaccharides. Thus, they enable, for example, to directly induce the apoptosis of malignant cells by the crosslinking of surface slowly internalizing receptors, or to deplete the efficacy of tumor‐associated proteins. The precise biorecognition of natural binding motifs by multiple vectors on the polymer construct remains the crucial part in the designing of these drug‐free nanomedicines. Here, the rationales, designs, synthetic approaches, and therapeutic potential of drug‐free macromolecular therapeutics consisting of various active vectors are described in detail. Recent developments and achievements for namely B‐cell lymphoma treatment, Gal‐3‐positive tumors, inflammative liver injury, and bacterial treatment are reviewed and highlighted. Finally, a possible future prospect within this highly exciting new field of nanomedicine research is presented.

“…The serum levels of soluble VCAM-1 appear to be correlated with the degree of atherosclerosis and may be used for diagnosing the early stages of the condition [ 8 ]. Endothelial activation, resulting in E-selectin expansion, induces leukocyte rolling along the vascular wall and mediates inflammation in various diseases, including atherosclerosis [ 9 ]. A common feature of the inflammatory process in psoriasis and atherosclerosis is leukocyte migration, to which VCAM-1 and E-selectin significantly contribute.…”

Section: Introductionmentioning

confidence: 99%

Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis

¹

,

Owczarczyk‐Saczonek

²

,

³

et al. 2020

View full text Add to dashboard Cite

Background and objectives: The shared pathogenesis of psoriasis and atherosclerosis may be determined by assaying the levels of endothelial activation molecules. This study aimed at evaluating vascular cell adhesion molecule 1 (VCAM-1) and E-selectin serum concentrations, and atherosclerosis severity in patients with plaque psoriasis. It also aimed to determine the effects of methotrexate/adalimumab treatment for 12 weeks on the plasma levels of the aforementioned molecules. Materials and Methods: The study included 34 psoriasis patients (17 treated with methotrexate and 17 treated with adalimumab) and eight controls. The 10-year risk of a fatal cardiovascular disease, body mass index, Psoriasis Area and Severity Index, and body surface area were calculated for each subject. VCAM-1 and E-selectin levels were determined via an enzyme-linked immunosorbent assay at baseline and after 12 weeks. Results: Baseline E-selectin and VCAM-1 levels were higher in the adalimumab group than in the methotrexate and control groups. VCAM-1 levels decreased in the adalimumab (p = 0.02) and methotrexate groups (p = 0.008), while E-selectin levels decreased in the methotrexate group (p = 0.004). Conclusions: The results indicate a correlation between systemic psoriasis treatment and E-selectin and VCAM-1 plasma concentrations, which may be associated with the risk of cardiovascular disease development.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.